Molecular subtypes and prognostic factors of lung large cell neuroendocrine carcinoma.

IF 4 2区 医学 Q2 ONCOLOGY Translational lung cancer research Pub Date : 2024-09-30 Epub Date: 2024-09-27 DOI:10.21037/tlcr-24-292
Tingting Liu, Xueyuan Chen, Silang Mo, Ting Zhou, Wenjuan Ma, Gang Chen, Xiang Chen, Mengting Shi, Yuwen Yang, Yan Huang, Hongyun Zhao, Wenfeng Fang, Yunpeng Yang, Jing Li, Li Zhang, Yuanyuan Zhao
{"title":"Molecular subtypes and prognostic factors of lung large cell neuroendocrine carcinoma.","authors":"Tingting Liu, Xueyuan Chen, Silang Mo, Ting Zhou, Wenjuan Ma, Gang Chen, Xiang Chen, Mengting Shi, Yuwen Yang, Yan Huang, Hongyun Zhao, Wenfeng Fang, Yunpeng Yang, Jing Li, Li Zhang, Yuanyuan Zhao","doi":"10.21037/tlcr-24-292","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lung large cell neuroendocrine carcinoma (LCNEC) is an aggressive disease with poor prognosis and short-term survival, which lacks effective prognostic indicators. The study aims to investigate the molecular subtypes and prognostic markers of lung LCNEC.</p><p><strong>Methods: </strong>Patients diagnosed with lung LCNEC at Sun Yat-sen University Cancer Center (SYSUCC) between November 2007 and January 2021 were screened. Baseline clinical data were collected and routine blood indexes including lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) were calculated. Immunohistochemistry (IHC) of ASCL1, NEUROD1, POU2F3, YAP1 were done to perform molecular subtyping, while CD56, Syn, CgA, CD3, CD8, CD20, CD68, and CD163 were also stained on tissue samples. Then prognostic factors of lung LCNEC were explored.</p><p><strong>Results: </strong>One hundred and fifty-one lung LCNEC patients were identified, 103 of whom had complete clinical information, available routine blood and biochemical indexes were eventually included in the present study. Tumor tissue specimens were available from 64 patients. Positive expression rates of ASCL1, NEUROD1, and YAP1 were 82.8%, 50.0%, and 28.1%, respectively. No POU2F3<sup>+</sup> cases were detected. Forty (62.5%) patients co-expressed with two or three markers. High LMR (>3.3) was an independent predictor of favorable prognosis of disease-free survival (DFS) [hazard ratio (HR), 0.391; 95% confidence interval (CI): 0.161-0.948; P=0.04] and overall survival (OS) (HR, 0.201; 95% CI: 0.071-0.574; P=0.003). Notably, high LMR was correlated with higher intra-tumoral CD3<sup>+</sup> (P=0.004), CD8<sup>+</sup> (P=0.01), and CD68<sup>+</sup> (P<0.001) immune cell infiltration compared to low LMR in lung LCNEC.</p><p><strong>Conclusions: </strong>Our study validated molecular subtypes by IHC in lung LCNEC, and co-expression was found among different subtypes, with no prognostic effect. High blood LMR level was associated with a favorable prognosis in lung LCNEC, which might partly reflect a hot tumor tissue immune microenvironment. Our findings may benefit clinical practice, and further studies are warranted.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11484736/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-24-292","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Lung large cell neuroendocrine carcinoma (LCNEC) is an aggressive disease with poor prognosis and short-term survival, which lacks effective prognostic indicators. The study aims to investigate the molecular subtypes and prognostic markers of lung LCNEC.

Methods: Patients diagnosed with lung LCNEC at Sun Yat-sen University Cancer Center (SYSUCC) between November 2007 and January 2021 were screened. Baseline clinical data were collected and routine blood indexes including lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) were calculated. Immunohistochemistry (IHC) of ASCL1, NEUROD1, POU2F3, YAP1 were done to perform molecular subtyping, while CD56, Syn, CgA, CD3, CD8, CD20, CD68, and CD163 were also stained on tissue samples. Then prognostic factors of lung LCNEC were explored.

Results: One hundred and fifty-one lung LCNEC patients were identified, 103 of whom had complete clinical information, available routine blood and biochemical indexes were eventually included in the present study. Tumor tissue specimens were available from 64 patients. Positive expression rates of ASCL1, NEUROD1, and YAP1 were 82.8%, 50.0%, and 28.1%, respectively. No POU2F3+ cases were detected. Forty (62.5%) patients co-expressed with two or three markers. High LMR (>3.3) was an independent predictor of favorable prognosis of disease-free survival (DFS) [hazard ratio (HR), 0.391; 95% confidence interval (CI): 0.161-0.948; P=0.04] and overall survival (OS) (HR, 0.201; 95% CI: 0.071-0.574; P=0.003). Notably, high LMR was correlated with higher intra-tumoral CD3+ (P=0.004), CD8+ (P=0.01), and CD68+ (P<0.001) immune cell infiltration compared to low LMR in lung LCNEC.

Conclusions: Our study validated molecular subtypes by IHC in lung LCNEC, and co-expression was found among different subtypes, with no prognostic effect. High blood LMR level was associated with a favorable prognosis in lung LCNEC, which might partly reflect a hot tumor tissue immune microenvironment. Our findings may benefit clinical practice, and further studies are warranted.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肺大细胞神经内分泌癌的分子亚型和预后因素。
背景:肺大细胞神经内分泌癌(LCNEC肺大细胞神经内分泌癌(LCNEC)是一种侵袭性疾病,预后差,短期生存率低,缺乏有效的预后指标。本研究旨在探讨肺LCNEC的分子亚型和预后标志物:方法:筛选2007年11月至2021年1月期间在中山大学肿瘤防治中心(SYSUCC)确诊的肺LCNEC患者。收集基线临床数据并计算血常规指标,包括淋巴细胞与单核细胞比值(LMR)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和全身免疫炎症指数(SII)。免疫组化(IHC)对 ASCL1、NEUROD1、POU2F3 和 YAP1 进行分子亚型鉴定,同时对组织样本进行 CD56、Syn、CgA、CD3、CD8、CD20、CD68 和 CD163 染色。然后探讨了肺LCNEC的预后因素:结果:本研究共发现 151 例肺 LCNEC 患者,其中 103 例患者具有完整的临床资料、血常规和生化指标。有 64 例患者提供了肿瘤组织标本。ASCL1、NEUROD1和YAP1的阳性表达率分别为82.8%、50.0%和28.1%。未发现 POU2F3+ 病例。40例(62.5%)患者同时表达两种或三种标记物。高LMR(>3.3)是无病生存期(DFS)[危险比(HR),0.391;95% 置信区间(CI):0.161-0.948;P=0.04]和总生存期(OS)(HR,0.201;95% CI:0.071-0.574;P=0.003)预后良好的独立预测因子。值得注意的是,高LMR与较高的瘤内CD3+(P=0.004)、CD8+(P=0.01)和CD68+(PConclusions:我们的研究通过 IHC 验证了肺部 LCNEC 的分子亚型,发现不同亚型之间存在共表达,但对预后无影响。高血液 LMR 水平与肺癌 LCNEC 的良好预后相关,这可能部分反映了热肿瘤组织免疫微环境。我们的研究结果可能会对临床实践有所裨益,值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
2.50%
发文量
137
期刊介绍: Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.
期刊最新文献
EGFR mutations in patients with lung adenocarcinoma and malignant pleural effusion: a propensity score-matched analysis of a single-center database. TFAP2A-activated ITGB4 promotes lung adenocarcinoma progression and inhibits CD4+/CD8+ T-cell infiltrations by targeting NF-κB signaling pathway. A multi-level investigation of the genetic relationship between gastroesophageal reflux disease and lung cancer. ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report. Association between fruit intake and non-small cell lung cancer: a Mendelian randomization study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1